Jonathan Yen News Today

BEACON Trial of BEAM-101 in Sickle Cell Disease Progressing with Consented Patients Projected to Fill Sentinel Cohort and to Initiate Expansion Cohort First Patient Consented in Phase 1/2 Trial of...

The study explores how Gene therapy that modifies haemoglobin can help in treating sickle cell disease and beta thalassemia. | Health

Adenosine base editing restarted fetal hemoglobin expression in cells from patients with sickle cell disease. Find how St. Jude & Broad are advancing to a cure.

Prime-edited hematopoietic stem cells from sickle cell disease patients can engraft and help treat genetic blood disorders in mice.

New study from St. Jude Childrens, MIT and Harvard shows a promising approach to treating sickle cell disease.

Scientists at St. Jude Children’s Research Hospital and the Broad Institute of MIT and Harvard showed how prime editing can correct the mutation that causes sickle cell disease in a potentially curative approach.

Broad Institute of MIT and Harvard Sickle cell disease (SCD) is the most common deadly genetic disorder, affecting more than 300,000 newborns worldwide each year. It leads to chronic pain, organ failure, and early death in patients. A team led by researchers at the Broad Institute of MIT and Harvard and St. Jude Children’s Research Hospital has now demonstrated a base editing approach that efficiently corrects the mutation underlying SCD in patient blood stem cells and in mice. This gene edit...

DBS will double its recruitment of financial planning advisers by the end of this year, by hiring over 650 wealth planning managers and insurance consultants - a new, self-employed role that the bank is rolling out with insurer Manulife Singapore. Read more at The Business Times.